SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Up 117.6% in June

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 6,872 shares, an increase of 117.6% from the May 31st total of 3,158 shares. Based on an average daily volume of 38,353 shares, the days-to-cover ratio is presently 0.2 days.

SAB Biotherapeutics Stock Performance

NASDAQ SABSW traded down $0.00 during midday trading on Wednesday, hitting $0.01. The company had a trading volume of 37,604 shares, compared to its average volume of 24,881. The firm has a fifty day simple moving average of $0.02 and a two-hundred day simple moving average of $0.03. SAB Biotherapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.18.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.